Showing 3171-3180 of 4166 results for "".
- Bausch + Lomb Announces New Scientific and Clinical Analyses to be Presented at American Academy of Optometry Annual Meetinghttps://modernod.com/news/bausch-lomb-announces-new-scientific-and-clinical-analyses-to-be-presented-at-american-academy-of-optometry-annual-meeting/2478386/Bausch + Lomb announced that three poster presentations will feature the company’s new silicone hydrogel (SiHy) daily disposable contact lens, Bausch + Lomb Infuse, during the virtual American Academy of Optometry (AAO) annual meeting (Oct. 7-22, 2020). “Over the past two decades, we have
- Nicox Reports on Enrollment Progress in Mont Blanc Phase 3 Clinical Trial in Glaucomahttps://modernod.com/news/nicox-reports-on-enrollment-progress-in-mont-blanc-phase-3-clinical-trial-in-glaucoma/2478024/Nicox SA announced that over 40 sites have been initiated in the first month of the phase 3 Mont Blanc trial, evaluating NCX 470 for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. NCX 470 is the company’s novel, second-generation nitric oxide (NO)-donating bimato
- Pfizer Aims to Start Clinical Testing of Lead Compound Against SARS-CoV-2 in Third Quarterhttps://modernod.com/news/pfizer-aims-to-start-clinical-testing-of-lead-compound-against-sars-cov-2-in-third-quarter/2477560/In an update on its efforts to combat COVID-19, Pfizer said results of initial screening assays have led it to zero in on a lead protease inhibitor with antiviral activity against SARS-CoV-2 based on preliminary data. The company stated that it will now perform preclinical testing on the compound
- American College of Surgeons Releases New Clinical Guidance Document For Elective Surgical Case Triage During COVID-19https://modernod.com/news/american-college-of-surgeons-releases-new-clinical-guidance-document-for-elective-surgical-case-triage-during-covid-19/2477456/To assist in surgical decision-making in curtailing cases, The American College of Surgeons (ACS) released “COVID-19: Elective Case Triage Guidelines for Surgical Care,” a new surgical triage document that was developed following expert review in several specialties and provides trust
- Regeneron’s Novel COVID-19 Antibody Program Has Potential to Enter Human Clinical Studies by Early Summerhttps://modernod.com/news/regenerons-novel-covid-19-antibody-program-has-potential-to-enter-human-clinical-studies-by-early-summer/2477404/Regeneron Pharmaceuticals announced the latest progress in its efforts to discover and develop a novel multi-antibody cocktail that can be administered as prophylaxis before exposure to the SARS-CoV-2 virus or as treatment for those already infected. Regeneron scientists have now isolated
- Ribomic Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet AMDhttps://modernod.com/news/ribomic-announces-first-injection-in-the-phase-2-clinical-trial-of-rbm-007-tofu-study-in-subjects-with-wet-amd/2477304/Ribomic announced that first patient has received injection in the phase 2 trial of RBM-007 for the treatment of wet age-related macular degeneration (AMD) in the United States. The first site started enrollment at the end of December 2019 and five sites are now active across the United States.</
- ForwardVue Pharma CEO: “Short Path to the Clinic” for Retinal Disease Treatmenthttps://modernod.com/news/forwardvue-pharma-ceo-short-path-to-the-clinic-for-retinal-disease-treatment/2477263/In an interview with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco, ForwardVue Pharmaceuticals CEO Alan Franklin, MD, PhD, who is an ophthalmologist, said the company’s lead molecule aims to treat retinal neovascular disease.
- The New England Journal of Medicine Publishes Comprehensive Data from Phase 3 Clinical Trial of Tepezza for Thyroid Eye Diseasehttps://modernod.com/news/the-new-england-journal-of-medicine-publishes-comprehensive-data-from-phase-3-clinical-trial-of-tepezza-for-thyroid-eye-disease/2477252/Horizon Therapeutics announced that The New England Journal of Medicine has published
- Analysis: FDA’s Efforts to Speed Drug Approval May Have Led to Less Rigorous Clinical Outcome Requirementshttps://modernod.com/news/analysis-fdas-efforts-to-speed-drug-approval-may-have-led-to-less-rigorous-clinical-outcome-requirements/2477231/An analysis published in JAMA suggests that efforts by the FDA to speed the development and approval of drugs may have led to a reduction in the amount of evidence available at the time of authorization by the agency and an increase in more surrogate measures. However, the authors noted
- AAO and Verana Health Accelerate Clinical Trials for Patients with Rare, Sight-Threatening Retinal Diseases Through Verana Trial Connecthttps://modernod.com/news/aao-and-verana-health-accelerate-clinical-trials-for-patients-with-rare-sight-threatening-retinal-diseases-through-verana-trial-connect/2476962/The American Academy of Ophthalmology (AAO) and Verana Health announced that they are now facilitating no-cost genetic testing and counseling for patients with certain inherited retinal diseases through Verana Trial Connect, a powerful cloud-based application that facilitates physician and patien